Search

Your search keyword '"de Boer, Jan"' showing total 14 results
Start Over Author "de Boer, Jan" Journal blood
14 results on '"de Boer, Jan"'

3. Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast

Author

de Boer, Mintsje, primary, Hauptmann, Michael, additional, Hijmering, Nathalie J., additional, van Noesel, Carel J. M., additional, Rakhorst, Hinne A., additional, Meijers-Heijboer, Hanne E. J., additional, de Boer, Jan Paul, additional, van der Hulst, René R. W. J., additional, de Jong, Daphne, additional, and van Leeuwen, Flora E., additional

Published
2020
Full Text
View/download PDF

4. Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Author

Armand, Philippe, primary, Engert, Andreas, additional, Younes, Anas, additional, Lee, Hun Ju, additional, Santoro, Armando, additional, Zinzani, Pier Luigi, additional, Timmerman, John M., additional, Collins, Graham P., additional, Ramchandren, Radhakrishnan, additional, Cohen, Jonathon B., additional, De Boer, Jan Paul, additional, Savage, Kerry J, additional, Kuruvilla, John, additional, Trněný, Marek, additional, Shipp, Margaret A., additional, Sacchi, Mariana, additional, Sumbul, Anne, additional, and Ansell, Stephen M., additional

Published
2018
Full Text
View/download PDF

5. Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Author

Cohen, Jonathon B., primary, Kuruvilla, John, additional, Engert, Andreas, additional, Ansell, Stephen M., additional, Younes, Anas, additional, Lee, Hun Ju, additional, Trněný, Marek, additional, Savage, Kerry J, additional, Ramchandren, Radhakrishnan, additional, Collins, Graham P., additional, Zinzani, Pier Luigi, additional, De Boer, Jan Paul, additional, Shipp, Margaret A., additional, Santoro, Armando, additional, Timmerman, John M., additional, Sacchi, Mariana, additional, Sy, Oumar, additional, and Armand, Philippe, additional

Published
2018
Full Text
View/download PDF

6. Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Author

Cohen, Jonathon B, primary, Engert, Andreas, additional, Ansell, Stephen M, additional, Younes, Anas, additional, Trneny, Marek, additional, Savage, Kerry J, additional, Ramchandren, Radhakrishnan, additional, Collins, Graham, additional, Fanale, Michelle A., additional, Armand, Philippe, additional, Zinzani, Pier Luigi, additional, De Boer, Jan Paul, additional, Shipp, Margaret A., additional, Santoro, Armando, additional, Timmerman, John M, additional, Sacchi, Mariana, additional, Sy, Oumar, additional, and Kuruvilla, John, additional

Published
2017
Full Text
View/download PDF

8. Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Author

Timmerman, John M., primary, Engert, Andreas, additional, Younes, Anas, additional, Santoro, Armando, additional, Armand, Philippe, additional, Fanale, Michelle A, additional, Collins, Graham P., additional, Ratanatharathorn, Voravit, additional, Kuruvilla, John, additional, Cohen, Jonathon B., additional, Savage, Kerry J, additional, Trneny, Marek, additional, De Boer, Jan Paul, additional, Shipp, Margaret A., additional, Rodig, Scott J, additional, Kato, Kazunobu, additional, Sumbul, Anne, additional, and Ansell, Stephen, additional

Published
2016
Full Text
View/download PDF

9. Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Author

Roemer, Margaretha G.M., Redd, Robert A., Cader, Fathima Zumla, Pak, Christine J., Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle A., Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M, Collins, Graham, Ramchandren, Rod, Cohen, Jonathon B, De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J, Trneny, Marek, Ansell, Stephen M, Sacchi, Mariana, Farsaci, Benedetto, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S., Pinkus, Geraldine S., Ligon, Azra H., Rodig, Scott J., and Shipp, Margaret A.

Published
2017
Full Text
View/download PDF

10. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

Author

van Eggermond, Anna M., primary, Schaapveld, Michael, additional, Lugtenburg, Pieternella J., additional, Krol, Augustinus D. G., additional, de Boer, Jan Paul, additional, Zijlstra, Josée M., additional, Raemaekers, John M. M., additional, Kremer, Leontien C. M., additional, Roesink, Judith M., additional, Louwman, Marieke W. J., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2014
Full Text
View/download PDF

11. Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.

Author

Hallaert, Delfine Y.H., primary, Spijker, Rene, additional, Jak, Margot, additional, Jaspers, Annelieke, additional, Derks, Ingrid A.M., additional, Alves, Nuno L., additional, de Boer, Jan Paul, additional, de Jong, Daphne, additional, Green, Simon R., additional, van Lier, Rene A.W., additional, van Oers, Marinus H.J., additional, and Eldering, Eric, additional

Published
2006
Full Text
View/download PDF

13. Late cardiotoxicity after treatment for Hodgkin lymphoma

Author

Aleman, Berthe M.P., van den Belt-Dusebout, Alexandra W., De Bruin, Marie L., van 't Veer, Mars B., Baaijens, Margreet H.A., de Boer, Jan Paul, Hart, Augustinus A.M., Klokman, Willem J., Kuenen, Marianne A., Ouwens, Gabey M., Bartelink, Harry, and van Leeuwen, Flora E.

Abstract

We assessed cardiovascular disease (CVD) incidence in 1474 survivors of Hodgkin lymphoma (HL) younger than 41 years at treatment (1965-1995). Multivariable Cox regression and competing risk analyses were used to quantify treatment effects on CVD risk. After a median follow-up of 18.7 years, risks of myocardial infarction (MI) and congestive heart failure (CHF) were strongly increased compared with the general population (standardized incidence ratios [SIRs] = 3.6 and 4.9, respectively), resulting in 35.7 excess cases of MI and 25.6 excess cases of CHF per 10 000 patients/year. SIRs of all CVDs combined remained increased for at least 25 years and were more strongly elevated in younger patients. Mediastinal radiotherapy significantly increased the risks of MI, angina pectoris, CHF, and valvular disorders (2- to 7-fold). Anthracyclines significantly added to the elevated risks of CHF and valvular disorders from mediastinal RT (hazard ratios [HRs] were 2.81 and 2.10, respectively). The 25-year cumulative incidence of CHF after mediastinal radiotherapy and anthracyclines in competing risk analyses was 7.9%. In conclusion, risks of several CVDs are 3- to 5-fold increased in survivors of HL compared with the general population, even after prolonged follow-up, leading to increasing absolute excess risks over time. Anthracyclines further increase the elevated risks of CHF and valvular disorders from mediastinal radiotherapy.

Published
2007
Full Text
View/download PDF

14. The Interaction of Plasminogen Activator Inhibitor 1 With Plasminogen Activators (Tissue-Type and Urokinase-Type) and Fibrin: Localization of Interaction Sites and Physiologic Relevance

Author

Keijer, Jaap, Linders, Marijke, van Zonneveld, Anton-Jan, Ehrlich, Hartmut J., de Boer, Jan-Paul, and Pannekoek, Hans

Abstract

Plasminogen activator inhibitor 1 (PAI-1), an essential regulatory protein of the fibrinolytic system, harbors interaction sites for plasminogen activators (tissue-type [t-PA] and urokinase-type [u-PA]) and for fibrin. In this study, anti-PAI-1 monoclonal antibodies (MoAbs) were used to identify interaction sites of PAI-1 with these components. The binding sites of 18 different MoAbs were established and are located on five distinct "linear" areas of PAI-1. MoAbs, binding to two distinct areas of PAI-1, are able to prevent the inhibition of t-PA by PAI-1. In addition, two interaction sites for fibrin were identified on PAI-1. The area located between amino acids 110 and 145 of PAI-1 contains a binding site for both components and its significance is discussed in the context of the t-PA inhibition by fibrin-bound PAI-1. Subsequently, the MoAbs were used to assess the role of platelet-PAI-1 in clot-lysis. An in vitro clot-lysis system was used to demonstrate that clot-lysis resistance is dependent on the presence of activated platelets and that PAI-1 is a major determinant for lysis-resistance. We propose that, upon activation of platelets, PAI-1 is fixed within the clot by binding to fibrin and retains its full capacity to inhibit t-PA and u-PA.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results